Iminosugars Inhibit Dengue Virus Production via Inhibition of ER Alpha-Glucosidases—Not Glycolipid Processing Enzymes

PLoS Neglected Tropical Diseases

Volumn 10, Issue 3, 2016, Pages

  Sayce, Andrew C ^a   Alonzi, Dominic S ^a   Killingbeck, Sarah S ^b   Tyrrell, Beatrice E ^a   Hill, Michelle L ^a   Caputo, Alessandro T ^a   Iwaki, Ren ^c   Kinami, Kyoko ^c   Ide, Daisuke ^c   Kiappes, J L ^a   Beatty, P Robert ^b   Kato, Atsushi ^c   Harris, Eva ^b   Dwek, Raymond A ^a   Miller, Joanna L ^a   Zitzmann, Nicole ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE; CASTANOSPERMINE; CASTANOSPERMINE 6 BUTYRATE; GLYCOLIPID; GLYCOPROTEIN; GLYCOSPHINGOLIPID; IMINOSUGAR; OLIGOSACCHARIDE; ANTIVIRUS AGENT; ENZYME INHIBITOR; INDOLIZINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DRUG EFFICACY; ENDOPLASMIC RETICULUM; ENZYME INHIBITION; FLUORESCENCE ACTIVATED CELL SORTING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MACROPHAGE; MOUSE; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY; STEREOCHEMISTRY; VIRAL PLAQUE ASSAY; VIRUS LOAD; ANIMAL; CELL CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MOLECULAR MODEL; PHYSIOLOGY; VIROLOGY; VIRUS RELEASE;

ALPHA-GLUCOSIDASES; ANIMALS; ANTIVIRAL AGENTS; CELLS, CULTURED; DENGUE VIRUS; ENDOPLASMIC RETICULUM; ENZYME INHIBITORS; HUMANS; IMINO SUGARS; INDOLIZINES; MACROPHAGES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; VIRUS RELEASE;

EID: 84960984777     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0004524     Document Type: Article

References (63)

1. Sayce AC, Miller JL, Zitzmann N, (2010) Targeting a host process as an antiviral approach against dengue virus. Trends Microbiol18: 323–330. doi: 10.1016/j.tim.2010.04.00320452219
2. Chang J, Wang L, Ma D, Qu X, Guo H, et al. (2009) Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses. Antimicrob Agents Chemother53: 1501–1508. doi: 10.1128/AAC.01457-0819223639
3. Courageot MP, Frenkiel MP, Dos Santos CD, Deubel V, Despres P, (2000) Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum. J Virol74: 564–572. 10590151
4. Gu B, Mason P, Wang L, Norton P, Bourne N, et al. (2007) Antiviral profiles of novel iminocyclitol compounds against bovine viral diarrhea virus, West Nile virus, dengue virus and hepatitis B virus. Antivir Chem Chemother18: 49–59. 17354651
5. Miller JL, Lachica R, Sayce AC, Williams JP, Bapat M, et al. (2012) Liposome-mediated delivery of iminosugars enhances efficacy against dengue virus in vivo. Antimicrob Agents Chemother56: 6379–6386. doi: 10.1128/AAC.01554-1223070155
6. Wu SF, Lee CJ, Liao CL, Dwek RA, Zitzmann N, et al. (2002) Antiviral effects of an iminosugar derivative on flavivirus infections. J Virol76: 3596–3604. 11907199
7. Yu W GT, Wang L, Du Y, Ye H, Qu X, Guo JT, Cuconati A, Zhao K, Block TM, Xu X, Chang J, . (2012) Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection. J Med Chem55: 6061–6075. doi: 10.1021/jm300171v22712544
8. Mehta A, Lu X, Block TM, Blumberg BS, Dwek RA, (1997) Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion. Proc Natl Acad Sci U S A94: 1822–1827. 9050863
9. Mehta A, Carrouee S, Conyers B, Jordan R, Butters T, et al. (2001) Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications. Hepatology33: 1488–1495. 11391538
10. Qu X, Pan X, Weidner J, Yu W, Alonzi D, et al. (2011) Inhibitors of endoplasmic reticulum alpha-glucosidases potently suppress hepatitis C virus virion assembly and release. Antimicrob Agents Chemother55: 1036–1044. doi: 10.1128/AAC.01319-1021173177
11. Tyms AS, Berrie EM, Ryder TA, Nash RJ, Hegarty MP, et al. (1987) Castanospermine and other plant alkaloid inhibitors of glucosidase activity block the growth of HIV. Lancet2: 1025–1026.
12. Hussain S, Miller JL, Harvey DJ, Gu Y, Rosenthal PB, et al. (2014) Strain-specific antiviral activity of iminosugars against human influenza A viruses. J Antimicrob Chemother.
13. Pan YT, Hori H, Saul R, Sanford BA, Molyneux RJ, et al. (1983) Castanospermine inhibits the processing of the oligosaccharide portion of the influenza viral hemagglutinin. Biochemistry22: 3975–3984. 6615812
14. Sunkara PS, Bowlin TL, Liu PS, Sjoerdsma A, (1987) Antiretroviral activity of castanospermine and deoxynojirimycin, specific inhibitors of glycoprotein processing. Biochem Biophys Res Commun148: 206–210. 2960321
15. Whitby K, Pierson TC, Geiss B, Lane K, Engle M, et al. (2005) Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J Virol79: 8698–8706. 15994763
16. Perry ST, Buck MD, Plummer EM, Penmasta RA, Batra H, et al. (2013) An iminosugar with potent inhibition of dengue virus infection in vivo. Antiviral Res98: 35–43. doi: 10.1016/j.antiviral.2013.01.00423376501
17. Rathore AP, Paradkar PN, Watanabe S, Tan KH, Sung C, et al. (2011) Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model. Antiviral Res92: 453–460. doi: 10.1016/j.antiviral.2011.10.00222020302
18. Watanabe S, Rathore AP, Sung C, Lu F, Khoo YM, et al. (2012) Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial. Antiviral Res96: 32–35. doi: 10.1016/j.antiviral.2012.07.00822867971
19. Chang J, Block TM, Guo JT, (2013) Antiviral therapies targeting host ER alpha-glucosidases: Current status and future directions. Antiviral Res99: 251–260. doi: 10.1016/j.antiviral.2013.06.01123816430
20. Naik NG, Wu HN, (2015) Mutation of Putative N-Glycosylation Sites on Dengue Virus NS4B Decreases RNA Replication. J Virol89: 6746–6760. doi: 10.1128/JVI.00423-1525878113
21. Limjindaporn T, Wongwiwat W, Noisakran S, Srisawat C, Netsawang J, et al. (2009) Interaction of dengue virus envelope protein with endoplasmic reticulum-resident chaperones facilitates dengue virus production. Biochem Biophys Res Commun379: 196–200. doi: 10.1016/j.bbrc.2008.12.07019105951
22. Alonzi DS, Neville DC, Lachmann RH, Dwek RA, Butters TD, (2008) Glucosylated free oligosaccharides are biomarkers of endoplasmic- reticulum alpha-glucosidase inhibition. Biochem J409: 571–580. 17868040
23. Chang J, Schul W, Butters TD, Yip A, Liu B, et al. (2011) Combination of alpha-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo. Antiviral Res89: 26–34. doi: 10.1016/j.antiviral.2010.11.00221073903
24. Lachmann RH, (2003) Miglustat. Oxford GlycoSciences/Actelion. Curr Opin Investig Drugs4: 472–479. 12808890
25. Platt FM, Neises GR, Dwek RA, Butters TD, (1994) N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem269: 8362–8365. 8132559
26. Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, et al. (2000) Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet355: 1481–1485. 10801168
27. Wichit S, Jittmittraphap A, Hidari KI, Thaisomboonsuk B, Petmitr S, et al. (2011) Dengue virus type 2 recognizes the carbohydrate moiety of neutral glycosphingolipids in mammalian and mosquito cells. Microbiol Immunol55: 135–140. doi: 10.1111/j.1348-0421.2010.00293.x21265875
28. Welsch S, Miller S, Romero-Brey I, Merz A, Bleck CKE, et al. (2009) Composition and Three-Dimensional Architecture of the Dengue Virus Replication and Assembly Sites. Cell Host & Microbe5: 365–375.
29. Chatel-Chaix L, Bartenschlager R, (2014) Dengue virus- and hepatitis C virus-induced replication and assembly compartments: the enemy inside—caught in the web. J Virol88: 5907–5911. doi: 10.1128/JVI.03404-1324623440
30. Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E, (2006) Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol80: 10208–10217. 17005698
31. Miller JL, de Wet BJ, Martinez-Pomares L, Radcliffe CM, Dwek RA, et al. (2008) The mannose receptor mediates dengue virus infection of macrophages. PLoS Pathog4: e17. doi: 10.1371/journal.ppat.004001718266465
32. Asano N, Nishida M, Kato A, Kizu H, Matsui K, et al. (1998) Homonojirimycin isomers and N-alkylated homonojirimycins: structural and conformational basis of inhibition of glycosidases. J Med Chem41: 2565–2571. 9651160
33. Russell PK, Nisalak A, Sukhavachana P, Vivona S, (1967) A plaque reduction test for dengue virus neutralizing antibodies. J Immunol99: 285–290. 6031202
34. Diamond MS, Roberts TG, Edgil D, Lu B, Ernst J, et al. (2000) Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons. J Virol74: 4957–4966. 10799569
35. Zor T, Selinger Z, (1996) Linearization of the Bradford protein assay increases its sensitivity: theoretical and experimental studies. Anal Biochem236: 302–308. 8660509
36. Neville DC, Coquard V, Priestman DA, te Vruchte DJ, Sillence DJ, et al. (2004) Analysis of fluorescently labeled glycosphingolipid-derived oligosaccharides following ceramide glycanase digestion and anthranilic acid labeling. Anal Biochem331: 275–282. 15265733
37. Svennerholm L, Fredman P, (1980) A procedure for the quantitative isolation of brain gangliosides. Biochim Biophys Acta617: 97–109. 7353026
38. Laue T, Emmerich P, Schmitz H, (1999) Detection of dengue virus RNA in patients after primary or secondary dengue infection by using the TaqMan automated amplification system. J Clin Microbiol37: 2543–2547. 10405398
39. Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, et al. (2010) Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog6: e1000790. doi: 10.1371/journal.ppat.100079020168989
40. Green AM, Beatty PR, Hadjilaou A, Harris E, (2014) Innate immunity to dengue virus infection and subversion of antiviral responses. J Mol Biol426: 1148–1160. doi: 10.1016/j.jmb.2013.11.02324316047
41. Olagnier D, Peri S, Steel C, van Montfoort N, Chiang C, et al. (2014) Cellular oxidative stress response controls the antiviral and apoptotic programs in dengue virus-infected dendritic cells. PLoS Pathog10: e1004566. doi: 10.1371/journal.ppat.100456625521078
42. Schmid MA, Harris E, (2014) Monocyte recruitment to the dermis and differentiation to dendritic cells increases the targets for dengue virus replication. PLoS Pathog10: e1004541. doi: 10.1371/journal.ppat.100454125474197
43. Platt FM, Neises GR, Karlsson GB, Dwek RA, Butters TD, (1994) N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing. J Biol Chem269: 27108–27114. 7929454
44. Glawar AF, Best D, Ayers BJ, Miyauchi S, Nakagawa S, et al. (2012) Scalable syntheses of both enantiomers of DNJNAc and DGJNAc from glucuronolactone: the effect of N-alkylation on hexosaminidase inhibition. Chemistry18: 9341–9359. doi: 10.1002/chem.20120011022736508
45. Mark BL, Mahuran DJ, Cherney MM, Zhao D, Knapp S, et al. (2003) Crystal structure of human beta-hexosaminidase B: understanding the molecular basis of Sandhoff and Tay-Sachs disease. J Mol Biol327: 1093–1109. 12662933
46. Karpas A, Fleet GW, Dwek RA, Petursson S, Namgoong SK, et al. (1988) Aminosugar derivatives as potential anti-human immunodeficiency virus agents. Proc Natl Acad Sci U S A85: 9229–9233. 3264071
47. Helt AM, Harris E, (2005) S-phase-dependent enhancement of dengue virus 2 replication in mosquito cells, but not in human cells. J Virol79: 13218–13230. 16227245
48. Knipe DaH PM, (2013) Fields Virology. Philadelphia, PA, USA: Lippincott Williams and Wilkins. 2456 p.
49. Schul W, Liu W, Xu HY, Flamand M, Vasudevan SG, (2007) A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis195: 665–674. 17262707
50. Low JG, Sung C, Wijaya L, Wei Y, Rathore AP, et al. (2014) Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial. Lancet Infect Dis14: 706–715. doi: 10.1016/S1473-3099(14)70730-324877997
51. Libraty DH, Young PR, Pickering D, Endy TP, Kalayanarooj S, et al. (2002) High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J Infect Dis186: 1165–1168. 12355369
52. Durantel D, Branza-Nichita N, Carrouee-Durantel S, Butters TD, Dwek RA, et al. (2001) Study of the mechanism of antiviral action of iminosugar derivatives against bovine viral diarrhea virus. J Virol75: 8987–8998. 11533162
53. Pavlovic D, Neville DC, Argaud O, Blumberg B, Dwek RA, et al. (2003) The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proc Natl Acad Sci U S A100: 6104–6108. 12719519
54. Steinmann E, Whitfield T, Kallis S, Dwek RA, Zitzmann N, et al. (2007) Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. Hepatology46: 330–338. 17599777
55. Woodhouse SD, Smith C, Michelet M, Branza-Nichita N, Hussey M, et al. (2008) Iminosugars in combination with interferon and ribavirin permanently eradicate noncytopathic bovine viral diarrhea virus from persistently infected cells. Antimicrob Agents Chemother52: 1820–1828. doi: 10.1128/AAC.01181-0718316522
56. Wong SS, Chebib M, Haqshenas G, Loveland B, Gowans EJ, (2011) Dengue virus PrM/M proteins fail to show pH-dependent ion channel activity in Xenopus oocytes. Virology412: 83–90. doi: 10.1016/j.virol.2010.12.05021262514
57. Premkumar A, Horan CR, Gage PW, (2005) Dengue virus M protein C-terminal peptide (DVM-C) forms ion channels. J Membr Biol204: 33–38. 16007501
58. Butters TD, Dwek RA, Platt FM, (2005) Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses. Glycobiology15: 43R–52R. 15901676
59. Venier RE, Igdoura SA, (2012) Miglustat as a therapeutic agent: prospects and caveats. J Med Genet49: 591–597. doi: 10.1136/jmedgenet-2012-10107022892202
60. Fleet GW, Karpas A, Dwek RA, Fellows LE, Tyms AS, et al. (1988) Inhibition of HIV replication by amino-sugar derivatives. FEBS Lett237: 128–132. 3169233
61. Block TM, Lu X, Platt FM, Foster GR, Gerlich WH, et al. (1994) Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin. Proc Natl Acad Sci U S A91: 2235–2239. 8134380
62. SG H, (2013) Celgosivir as a Treatment Against Dengue (CELADEN). National Library of Medicine (US).
63. Olson LJ, Orsi R, Alculumbre SG, Peterson FC, Stigliano ID, et al. (2013) Structure of the lectin mannose 6-phosphate receptor homology (MRH) domain of glucosidase II, an enzyme that regulates glycoprotein folding quality control in the endoplasmic reticulum. J Biol Chem288: 16460–16475. doi: 10.1074/jbc.M113.45023923609449